G007-LK: Specific Tankyrase 1/2 Inhibitor for Wnt/β-catenin and APC Mutation Cancer Research

Executive Summary: G007-LK is a small-molecule inhibitor that selectively targets tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), key enzymes in poly(ADP-ribosyl)ation and Wnt/β-catenin pathway regulation (Jia et al., 2017). It demonstrates nanomolar potency, with IC₅₀ values of 46 nM (TNKS1) and 25 nM (TNKS2) and inhibits Wnt signaling in cellular models with an IC₅₀ of 0.05 μM [APExBIO]. G007-LK induces β-catenin degradation and AXIN1/2 stabilization in APC-mutant colorectal cancer cells, reducing tumor growth in xenograft models. Its application extends to regulating Hippo pathway signaling by modulating YAP/TAZ activity. These features make G007-LK, distributed by APExBIO, a precision research tool for dissecting Wnt/β-catenin and related oncogenic pathways.

Biological Rationale

Tankyrases (TNKS1 and TNKS2) are members of the poly(ADP-ribose) polymerase (PARP) family and regulate protein homeostasis via poly(ADP-ribosyl)ation. They are implicated in Wnt/β-catenin signaling, telomere maintenance, and cell cycle progression [Jia et al., 2017]. Dysregulation of tankyrase activity is associated with tumorigenesis, particularly in colorectal cancer with APC mutations and in hepatocellular carcinoma, where elevated TNKS expression is observed. Inhibition of tankyrases destabilizes β-catenin by stabilizing AXIN1/2, leading to decreased Wnt pathway activity and reduced proliferation in cancer cells. The Hippo pathway, through YAP/TAZ regulation, is also directly influenced by tankyrase inhibition, highlighting the broader impact of these enzymes in cancer biology.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK is a small-molecule inhibitor that binds to the catalytic PARP domain of TNKS1 and TNKS2. It blocks their auto-poly(ADP-ribosyl)ation activity, measured by IC₅₀ values of 46 nM (TNKS1) and 25 nM (TNKS2), under in vitro conditions [APExBIO]. In cellular assays, G007-LK inhibits Wnt3a-induced ST-Luc reporter activity in HEK 293 cells with an IC₅₀ of 0.05 μM. In APC-mutant colorectal cancer cells such as SW480, it induces the formation of degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin, resulting in the proteasomal degradation of β-catenin. G007-LK also prevents tankyrase-mediated degradation of AXIN1/2, thereby stabilizing the β-catenin destruction complex. In hepatocellular carcinoma cells, G007-LK downregulates YAP protein levels and increases AMOTL1/2, negative regulators of YAP, thereby modulating Hippo pathway signaling (Jia et al., 2017).

Evidence & Benchmarks

• G007-LK inhibits TNKS1 and TNKS2 auto-poly(ADP-ribosyl)ation with IC₅₀ values of 46 nM and 25 nM, respectively, as determined in biochemical enzyme assays (APExBIO product page).
• In Wnt3a-stimulated HEK 293 cells, G007-LK suppresses Wnt signaling reporter ST-Luc activity with an IC₅₀ of 0.05 μM (APExBIO).
• In SW480 colorectal cancer cells, G007-LK induces formation of degradasomes and reduces cytosolic and nuclear β-catenin levels (internal article).
• In COLO-320DM xenograft mouse models, G007-LK administration reduces tumor volume and decreases TNKS1/2 and β-catenin protein levels while increasing AXIN1/2 stability (APExBIO).
• G007-LK inhibits proliferation of hepatocellular carcinoma cell lines and downregulates YAP/TEAD reporter activity, accompanied by upregulation of AMOTL1/2 proteins (Jia et al., 2017).

Applications, Limits & Misconceptions

G007-LK is used to study Wnt/β-catenin signaling, APC mutation colorectal cancer, and Hippo pathway modulation in cancer biology. Its nanomolar potency and selectivity for TNKS1/2 enable precise dissection of tankyrase-dependent mechanisms. The compound is suitable for in vitro biochemical assays, cell-based reporter assays, and in vivo xenograft models. Researchers can use G007-LK to explore crosstalk between Wnt/β-catenin and Hippo/YAP signaling, as well as to benchmark new tankyrase inhibitors. However, the compound is not soluble in water or ethanol, limiting some assay formats. Its effects are dependent on cellular context, especially the presence of functional APC or other destruction complex components.

This article expands on the mechanistic analysis in ‘G007-LK Tankyrase 1/2 Inhibitor: Unveiling Novel Mechanisms’ by providing updated in vivo benchmarks and clarification on Hippo pathway involvement. For a workflow perspective, see ‘G007-LK: Precision Tankyrase 1/2 Inhibitor for Wnt Signal…’, which this article complements by detailing product handling and experimental conditions. For translational research outlook, ‘Translational Frontiers with G007-LK…’ synthesizes experimental best practices, which are further contextualized here for APC-mutant colorectal and hepatocellular carcinoma models.

Common Pitfalls or Misconceptions

• G007-LK is not effective in cell lines lacking functional Wnt/β-catenin pathway components (e.g., non-APC-mutant backgrounds).
• The compound is insoluble in water and ethanol; improper solvent choice leads to precipitation and loss of activity.
• Long-term storage of G007-LK in solution can result in degradation; storage as a solid at -20°C is recommended.
• G007-LK targets tankyrase 1/2 specifically; it does not directly inhibit other PARP family members.
• Effects on YAP/TAZ activity are indirect and context-dependent, requiring presence of AMOTL1/2 and functional Hippo components.

Workflow Integration & Parameters

For optimal use, dissolve G007-LK at ≥26.5 mg/mL in DMSO, warming to 37°C or using an ultrasonic bath if necessary. Avoid aqueous or alcoholic solvents due to insolubility. Store solid G007-LK at -20°C; minimize time in solution and avoid repeated freeze-thaw cycles. For cell-based assays, titrate doses from 10 nM to 1 μM to determine minimal effective concentration. In in vivo studies, reconstitute immediately prior to administration and monitor for precipitation. APExBIO supplies G007-LK as SKU B5830, accompanied by technical documentation for research use only. For detailed workflow troubleshooting and reproducibility strategies, consult this workflow-focused article.

Conclusion & Outlook

G007-LK is a validated, potent tankyrase 1/2 inhibitor with broad utility in dissecting Wnt/β-catenin and Hippo pathway-driven oncogenesis. Its high selectivity and robust biochemical benchmarks support its use in APC mutation colorectal cancer and hepatocellular carcinoma models. Future studies may leverage G007-LK to develop synergistic therapies targeting Wnt and Hippo pathways. APExBIO continues to provide comprehensive support for research applications, ensuring that advances in tankyrase inhibition translate into improved experimental rigor and mechanistic insight.